ADMA Biologics, Inc. revised financial guidance for the years 2024 and 2025. For the years 2024 and 2025, the company expects total revenue now to be more than $330 million and $380 million, respectively, increased from prior guidance of $320 million and $370 million, respectively.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.845 USD | +27.63% | +30.40% | +96.46% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.46% | 1.61B | |
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-14.09% | 32.43B | |
+55.89% | 24.28B | |
-16.05% | 15.52B | |
-41.29% | 12.17B | |
-15.54% | 12.01B | |
-11.75% | 12B | |
+7.87% | 8.87B |
- Stock Market
- Equities
- ADMA Stock
- News ADMA Biologics, Inc.
- ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025